BioPharma Dive

Zag Bio emerges with plans to treat immune disease by targeting the thymus

With $80 million in funding from a list of high-profile backers, the startup is developing bifunctional antibodies that drag ...

Researcher provides new hope in managing diabetic ketoacidosis

A researcher at the University of Houston finds management of diabetic ketoacidosis may center around reducing ketone levels ...
BioPharma Dive

FDA places formal hold on two Intellia CRISPR trials

Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that ...

New to Growth Stocks? Here's 1 Every Investor Should Have on Their Radar.

New to Growth Stocks? Here's 1 Every Investor Should Have on Their Radar. CRISPR Therapeutics has an approved gene-editing therapy, Casgevy, which can be a game changer for patients who need it. The ...
ZME Science on MSN

A Rogue Gene Explains Mysterious Cases of Diabetes and Epilepsy in Newborns

When six infants around the world were diagnosed with an odd trio of symptoms (diabetes, epilepsy, and abnormally small heads ...

RNA modifications control how stem cells develop into retinal cells, research demonstrates

Cells contain a blueprint in the form of DNA that dictates what they can make. This blueprint is converted into a message ...
Reuters

Nobel Prize winners convince court to revive CRISPR patent dispute

May 12 (Reuters) - The University of California and the University of Vienna on Monday convinced a U.S. appeals court to revive their bid for patent rights to groundbreaking CRISPR gene-editing ...